Supercharge Your Innovation With Domain-Expert AI Agents!

Compositions and methods for treating non-alcoholic steatohepatitis

A non-alcoholic, fatty liver technology, applied in drug combinations, active ingredients of heterocyclic compounds, pharmaceutical formulations, etc.

Pending Publication Date: 2021-04-13
ALGERNON PHARMA INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Drugs currently used to treat NAFLD and NASH may help increase fat loss and / or improve biomedical marker levels, but no drug can reverse or reduce NAFLD and NASH once liver scarring has begun

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating non-alcoholic steatohepatitis
  • Compositions and methods for treating non-alcoholic steatohepatitis
  • Compositions and methods for treating non-alcoholic steatohepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0125] Materials and methods

[0126] Male neonatal C57BL / 6 mice were used. All mice were obtained from pathogen-free 14-day pregnant mice obtained from Japan SLC, Inc. (Hamamatsu, Japan) before the study began.

[0127] Murine STAM for NASH-HCC was performed according to previously described methods known in the art TM Model (Takakura et al., Characterization of non-alcoholic steatohepatitis, Anticancer Res, 34(9):4849-55 (2014); Fujii et al. (2013)). Male mice were given a single subcutaneous injection of 200 μg streptozotocin (STZ, Sigma, Missouri, USA) at 2 days after birth and fed a high-fat diet (CLEA Japan Inc) ad libitum with continuous feeding. , Tokyo, Japan) after 4 weeks of age (day 28±2), male mice were induced with NASH.

[0128] After induction of NASH, mice were randomly divided into 12 separate study groups of 8 6-week-old (42±2 days) mice based on body weight on the day before treatment initiation.

[0129] One day after randomization, mice were given o...

Embodiment 2

[0156] Materials and methods

[0157] Male neonatal C57BL / 6 mice were used as previously described. All mice were obtained from pathogen-free 14-day pregnant mice obtained from Japan SLC, Inc. (Hamamatsu, Japan) before the study began.

[0158] Murine STAM for NASH-HCC was performed according to previously described methods known in the art TM Model (Takakura et al., Characterization of non-alcoholic steatohepatitis, Anticancer Res, 34(9):4849-55 (2014); Fujii et al. (2013)) . Male mice were given a single subcutaneous injection of 200 μg streptozotocin (STZ, Sigma, Missouri, USA) at 2 days after birth and fed a high-fat diet (CLEA Japan Inc) ad libitum with continuous feeding. , Tokyo, Japan) after 4 weeks of age (day 28±2), male mice were induced with NASH.

[0159] After induction of NASH, the mice were randomly divided into 7 separate study groups of 8 6-week-old (42 ± 2 days) mice according to the body weight of the mice on the day before the start of treatment.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Cepharanthine, Repirinast, Ifenoprodil Hemitartrate, Bromantane, Actarit, Lobenzarit, Irsogladine, Istradefylline, Trapadil, Bemithyl, and are used for treating or prophylaxis of lobular inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis in a subject.

Description

[0001] References to related applications [0002] This application claims priority to U.S. Provisional Application 62 / 694,848, filed July 6, 2018, and U.S. Provisional Application 62 / 809,351, filed February 22, 2019, the contents of which are incorporated herein by reference. [0003] field of invention [0004] The present invention relates to the use of the compound for treating nonalcoholic fatty liver disease, especially the use of the compound for treating nonalcoholic fatty liver disease, nonalcoholic fatty liver and nonalcoholic steatohepatitis. Background technique [0005] Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions characterized by excess fat storage in liver cells. As the name suggests, the cause is usually not related to alcohol consumption. This is different from alcoholic liver disease caused by heavy drinking. Most commonly, NAFLD is nonalcoholic simple fatty liver or nonalcoholic steatohepatitis (NASH). [0006] Non...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/53A61K31/136A61K31/196A61K31/4184A61K31/4468A61K31/4741A61K31/519A61K31/522A61P1/16
CPCA61K31/136A61K31/522A61K31/4741A61K31/53A61K31/519A61K31/196A61P1/16A61K31/4184A61K31/4745A61K31/445A61K45/06A61K31/167A61K31/13
Inventor M·威廉姆斯
Owner ALGERNON PHARMA INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com